Participated · Seed · Jul 2026

Velocity builds infrastructure to help AI-native software companies monetize user intent through a stack that includes an AI-native advertising network, a mediation and auction layer, and a conversation intelligence system that turns multi-turn dialogue into privacy-safe intent signals. The company positions its product as complementary to subscriptions, enabling developers to expand free access while adding revenue without degrading engagement. Velocity says early customers, including Leadtech/MAU and AIBY (Chaton), have achieved meaningful monetization outcomes alongside healthy engagement and retention metrics. The startup raised $27 million in seed funding to further develop and scale its platform. Investors view Velocity as addressing a growing commercial challenge in the AI era—converting rapid user growth into sustainable revenue—and backing infrastructure that supports monetization and distribution.

Participated · Seed · Jun 2026

Shifters builds supervised autonomous ground robotic teams that enable operators to coordinate mission-configurable robots to enter, sense and operate in dangerous environments ahead of people. Its platform combines AI decision-making, mission orchestration and modular robotic systems designed with Modular Open Systems Approach (MOSA) principles, robust APIs and partner integration. The company has completed demonstrations of coordinated robotic entry and navigation capabilities with defense and security stakeholders. Reported use cases span defense and national security (reconnaissance, intelligence gathering, perimeter monitoring and high-risk mission preparation) as well as commercial applications like infrastructure inspections, agriculture, mining and search and rescue. Shifters is headquartered in Washington, D.C. and operates in the U.S., Middle East and Europe. Financially, the company has raised $10.2 million in this seed round, bringing total funding to $15 million to support AI development, manufacturing readiness and global expansion.

Participated · Seed · Jan 2026

Founded in 2024 and based in Portland, OR, AheadComputing is developing a breakthrough CPU microarchitecture that marries RISC-V extensibility with proprietary design to maximize per-core performance for AI inference, agentic AI, and other data-center tasks. The 120-person team, which collectively holds hundreds of compute patents and has shipped more than 70 products in prior roles, is currently building its first high-performance general-purpose CPU. The company positions its architecture as a critical complement to GPUs, arguing that CPU performance is still essential as 70% of data-center workloads are expected to be AI-related by 2030. Proceeds from recent funding are earmarked for R&D, software innovation, and test-chip development, as well as continued team expansion. Key technical collaborations include Alchip, Cadence, Skyechip, and Tenstorrent. To date, the company has raised $53 million, giving it runway to bring its initial product to market and further integrate RISC-V into mainstream AI infrastructure.

Participated · Seed · Jul 2025

Receive is a U.S.-based financial technology company offering an Earned Revenue Access platform that converts pending sales into immediate spending power for SMBs. Its core product allows merchants to access earned revenue without interest, credit checks, or traditional underwriting. Receive has a white-labeled partnership model enabling ISOs, payment processors, and software providers to leverage first‑party data and create new revenue streams. The company launched the SmartPay Calendar repayment tool and partnered with Titanium Payments to roll out the Titanium Boost Business Mastercard, which turns pending settlements into real-time spending power for Titanium merchants. Receive announced a $4 million seed round led by NGVP, has total funding of $7.1 million, and is supported by additional debt financing. Founder Ariel Blum, formerly in leadership roles at Melio, Green Dot, and American Express, started Receive to address SMB cash-flow challenges and help businesses reinvest sooner without taking on debt.

Participated · Series A · Feb 2024

Latigo Biotherapeutics is a clinical-stage biotech focused on developing best-in-class non-opioid pain medicines that target pain at its source via selective Nav1.8 inhibition. Its lead candidate, LTG-001, is an oral selective Nav1.8 inhibitor for acute pain and reported positive Phase 1 first-in-human results, showing it was well tolerated with rapid absorption. A second oral Nav1.8 inhibitor, LTG-305, is in Phase 1 trials aimed at chronic pain and is being evaluated for safety, tolerability, and pharmacokinetics. The company’s stated goal is to provide effective, rapid-acting pain relief without the risk of addiction. Latigo recently closed a $150 million Series B to support advancement of its Nav1.8 clinical programs and the development of a broader pipeline. The company is based in Thousand Oaks, Calif. Latigo Biotherapeutics is a Thousand Oaks, CA-based clinical-stage biotech focused on non-opioid pain therapeutics that act on the fundamental mechanism of pain transduction. The company uses proprietary in-house technology that applies AI, machine learning, structure-based, and knowledge-based design to generate drugs against targets validated by human genetics. Its lead program, LTG-001, is an oral, selective Nav1.8 inhibitor currently in a Phase 1 clinical trial in healthy volunteers intended to treat acute and chronic pain. Latigo also maintains a suite of Nav1.8 inhibitors to address the broader clinical potential of the target and has additional small-molecule discovery programs against genetically identified targets. Leadership changes accompanying the financing include the appointment of Desmond Padhi as interim CEO and Nancy Stagliano as chair of the board. The company intends to use the proceeds to support continued advancement of its portfolio of novel pain therapeutics.